NCT02642289

Brief Summary

This study evaluates the benefits of probiotics in patients with fibromyalgia syndrome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2015

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

December 21, 2015

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 30, 2015

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2016

Completed
Last Updated

March 14, 2016

Status Verified

March 1, 2016

Enrollment Period

2 months

First QC Date

December 21, 2015

Last Update Submit

March 11, 2016

Conditions

Keywords

Probiotics

Outcome Measures

Primary Outcomes (1)

  • Change Scores on Working memory and attentional control

    Corsi task

    Time Frame: At baseline and 8 weeks

Secondary Outcomes (12)

  • Change Scores on Body Composition

    Time Frame: At baseline and 8 weeks

  • Changes Scores on Cholinergic response indicators (%)

    Time Frame: At baseline and 8 weeks

  • Changes Scores on Heart rate variability.

    Time Frame: At baseline and 8 weeks

  • Changes Scores on Valsalva ratio. K30/15.

    Time Frame: At baseline and 8 weeks

  • Changes Scores on Systemic vascular resistance.

    Time Frame: At baseline and 8 weeks

  • +7 more secondary outcomes

Study Arms (3)

Probiotic1: Lactobacillus acidophilus

EXPERIMENTAL

Dietary Supplement: Probiotics 1. 8-week probiotic food-supplement intervention with Lactobacillus acidophilus (Daily intake: 24 millions)

Dietary Supplement: Lactobacillus acidophilus

Placebo

PLACEBO COMPARATOR

Inactivate substance

Other: Placebo

Probiotic2: Lactobacillus Rhamnosus GG ®

EXPERIMENTAL

Dietary Supplement: Probiotics 2 8-week probiotic food-supplement intervention with Lactobacillus Rhamnosus (Daily intake: 24 millions)

Dietary Supplement: Lactobacillus Rhamnosus GG ®

Interventions

Lactobacillus acidophilusDIETARY_SUPPLEMENT

Probiotic 5000, a commercial probiotic product provided by the company "Complementos Fitonutricionales, S.L."

Probiotic1: Lactobacillus acidophilus

Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab "Laboratorios Nutergia"

Probiotic2: Lactobacillus Rhamnosus GG ®
PlaceboOTHER

Innocuous substance

Placebo

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Fibromyalgia syndrome diagnosis.
  • No treatment with antibiotic.
  • More than a year of diagnosis
  • Agreement to participate in the study.

You may not qualify if:

  • Severe physical disability.
  • Malignancy.
  • Pregnancy
  • Psychiatric illnesses (eg, schizophrenia or substance abuse).
  • Medication usage other than as-needed analgesics (excluding long-term narcotics).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pablo Roman

Almería, Almeria, 04120, Spain

Location

MeSH Terms

Conditions

Fibromyalgia

Interventions

Lacteol

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System Diseases

Study Officials

  • Angeles Fernandez, PhD

    Universidad de Almeria

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
PhD Student

Study Record Dates

First Submitted

December 21, 2015

First Posted

December 30, 2015

Study Start

December 1, 2015

Primary Completion

February 1, 2016

Study Completion

February 1, 2016

Last Updated

March 14, 2016

Record last verified: 2016-03

Locations